Dermata Therapeutics, Inc. (DRMA)

2.3900 +0.1000 (+4.37%) 收市：04:00PM EDT

Dermata Therapeutics, Inc.

3525 Del Mar Heights Road
Suite 332
San Diego, CA 92130
United States
858 800 2543
https://www.dermatarx.com

版塊: Healthcare
行業: Biotechnology
全職員工: 8

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Gerald T. Proehl	Founder, President, CEO & Chairman	392k	無	1959
Mr. David F. Hale	Co-Founder & Lead Independent Director	73k	無	1949
Ms. Kyri K. Van Hoose CPA, M.B.A.	Senior VP & CFO	415.8k	無	1978
Dr. Christopher J. Nardo M.P.H., Ph.D.	Senior VP & Chief Development Officer	443.52k	無	1965
Mr. Sean Proehl	Senior Director of Legal & Business Development	無	無	無
Dr. Maria Bedoya Toro Munera M.B.A., Ph.D.	Senior Vice President of Regulatory Affairs & Quality Assurance	27.04k	無	1951

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

公司管治

截至 無 止，Dermata Therapeutics, Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。